1. Home
  2. REVB vs HSDT Comparison

REVB vs HSDT Comparison

Compare REVB & HSDT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • REVB
  • HSDT
  • Stock Information
  • Founded
  • REVB 2020
  • HSDT N/A
  • Country
  • REVB United States
  • HSDT United States
  • Employees
  • REVB N/A
  • HSDT 21
  • Industry
  • REVB Biotechnology: Pharmaceutical Preparations
  • HSDT Biotechnology: Electromedical & Electrotherapeutic Apparatus
  • Sector
  • REVB Health Care
  • HSDT Health Care
  • Exchange
  • REVB Nasdaq
  • HSDT Nasdaq
  • Market Cap
  • REVB 4.4M
  • HSDT 6.4M
  • IPO Year
  • REVB N/A
  • HSDT N/A
  • Fundamental
  • Price
  • REVB $2.87
  • HSDT $6.00
  • Analyst Decision
  • REVB
  • HSDT Hold
  • Analyst Count
  • REVB 0
  • HSDT 1
  • Target Price
  • REVB N/A
  • HSDT N/A
  • AVG Volume (30 Days)
  • REVB 87.7K
  • HSDT 27.8K
  • Earning Date
  • REVB 11-07-2025
  • HSDT 08-14-2025
  • Dividend Yield
  • REVB N/A
  • HSDT N/A
  • EPS Growth
  • REVB N/A
  • HSDT N/A
  • EPS
  • REVB N/A
  • HSDT N/A
  • Revenue
  • REVB N/A
  • HSDT $295,000.00
  • Revenue This Year
  • REVB N/A
  • HSDT N/A
  • Revenue Next Year
  • REVB N/A
  • HSDT $75.13
  • P/E Ratio
  • REVB N/A
  • HSDT N/A
  • Revenue Growth
  • REVB N/A
  • HSDT N/A
  • 52 Week Low
  • REVB $2.11
  • HSDT $5.37
  • 52 Week High
  • REVB $60.48
  • HSDT $1,200.00
  • Technical
  • Relative Strength Index (RSI)
  • REVB 56.54
  • HSDT 28.43
  • Support Level
  • REVB $2.65
  • HSDT $5.81
  • Resistance Level
  • REVB $2.88
  • HSDT $6.57
  • Average True Range (ATR)
  • REVB 0.19
  • HSDT 0.34
  • MACD
  • REVB 0.03
  • HSDT 0.84
  • Stochastic Oscillator
  • REVB 88.00
  • HSDT 24.18

About REVB Revelation Biosciences Inc.

Revelation Biosciences Inc is a clinical-stage life science company that is focused on rebalancing inflammation to optimize health using its proprietary formulation Gemini. It is developing a pipeline of potential high-value products based on Gemini. Gemini is Revelation's proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD) an established TLR4 agonist that can stimulate the human body's innate immune response to prevent and treat disease. The product candidates are developed are based on Gemini formulation of PHAD. Gemini-based programs consist of: Gemini-SSI developed for the prevention of surgical site infection (SSI); Gemini-AKI developed for the prevention of acute kidney injury (AKI); and Gemini-CKD for the treatment of chronic kidney disease (CKD).

About HSDT Helius Medical Technologies Inc. (DE)

Helius Medical Technologies Inc is a neurotech company focused on neurological wellness. The company's purpose is to develop, license, or acquire non-invasive technologies targeted at reducing symptoms of neurological disease or trauma. The company's product, known as the Portable Neuromodulation Stimulator (PoNS) is authorized for sale in Canada as a class II, a non-implantable medical device intended for use as a short-term treatment of gait deficit due to symptoms from multiple sclerosis and balance deficit due to mild-to-moderate traumatic brain injury and is to be used in conjunction with supervised therapeutic exercise.

Share on Social Networks: